ClinicalTrials.gg
CompletedNCT02869022Updated Jan 18, 2020

Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation

A Phase 3 interventional study of Custodiol-N and Custodiol in Heart Failure, sponsored by Dr. F. Köhler Chemie GmbH. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Dr. F. Köhler Chemie GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 600 studies in Heart Failure with a site in Germany — 107 open to participants now, 137 under way, 19 of them phase 3. Heart Failure · Germany.

Enrollment
232nd of 386
105 · median 161
Started
2016
with 29 others
Phase 3
81 of 600
15 open now
Registered
274th of 600
by date

Among the 600 studies in Heart Failure with a site in Germany, this one is the 232nd largest by enrollment of the 386 interventional ones that give a count, is one of 30 that started in 2016, is one of 81 in phase 3, and was the 274th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

107 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:

102 more — sign in →

All 107 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Heart Failure with a site in Germany, or all of them as a file.
02

Study summary

The objective of this investigation is to demonstrate non-inferiority in outcome of Custodiol-N against Custodiol in heart transplantation.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Donor criteria:

  • deceased donors should fulfil the criteria for organ donation (SCD) Patient criteria
  • recipients awaiting their first transplant
  • recipients ≥ 18 and >/= 65 years
  • recipient's signed
  • waiting list

Exclusion criteria

Exclusion Criteria:

Donor criteria:

  • not applicable

Patient criteria:

  • recipients participating in another interventional study
  • pregnant or lactating patients
  • history/demonstration of antibodies or AIDS
  • multiorgan transplantation
  • transMedics pump
  • the explantation team is affiliated another clinic than transplantation team
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Custodiol-N

    comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation

    Drug: Custodiol-N · Procedure: organ perfusion for heart transplantation

  • Active comparator
    Custodiol

    comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation

    Drug: Custodiol · Procedure: organ perfusion for heart transplantation

Interventions

06

What researchers measure

Primary outcomes

  1. Creatine kinase Myocard type "CK-MB" peak value

    day 1: measurements 4, 8, 12, 16, 20, 24 hours ± 30 min; day 2-3: measurements 8, 16 and 24 hours ± 2 hours; day 4-7 one time/day

    Time frame: from 4 to 168 hours after release of the aortic cross clamp

Secondary outcomes

  1. Catecholamine requirement

    defined as "yes" or "no"

    Time frame: from entry to the trial up to day 7

  2. Patient survival

    Time frame: at 7 days and 1, 3 and 12 months

  3. Complications

    occurrence, severity, type, and duration

    Time frame: from the time of the transplantation up to day 7

07

Study locations

9 sites
  • Universitätsklinik für Chirurgie-Klin. Abteilung für Herzchirurgie, MUW-AKH Wien
    Wien, 1090, Austria
  • Klinik für Thorax- und Kardiovaskularchirurgie, Herz- und Diabeteszentrum NRW
    Bad Oeynhausen, 32545, Germany
  • Klinik für Herz-, Thorax- und Gefäßchirurgie, Deutsches Herzzentrum Berlin
    Berlin, 13353, Germany
  • Klinik für Kardiovaskuläre Chirurgie, Universitätsklinikum Düsseldorf
    Düsseldorf, 40225, Germany
  • Klinik für Herz- und Gefäßchirurgie, Universitätszentrum Freiburg Bad Krotzingen
    Freiburg, 79106, Germany
  • Klinik für Gefäßchirurgie, Universitäres Herzzentrum am UKE Hamburg
    Hamburg, 20246, Germany
  • Abt. Herzchirugie, Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena
    Jena, 07747, Germany
  • Herz- Thorax- und herznahe Gefäßchirurgie, Klinikum der Universität Regensburg
    Regensburg, 93042, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Sep 2019, 38 months.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 38 months is close to that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2015
First posted
Aug 16, 2016
StartActual
Jul 2016
Primary completionActual
Sep 2, 2019
CompletionActual
Sep 2, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02869022
Lead sponsor
Dr. F. Köhler Chemie GmbH
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Jul 2016
Primary completion
Sep 2, 2019
Completion
Sep 2, 2019
Last update
Jan 18, 2020

Study contacts

Gabor Szabo, Prof. Dr.
principal investigator · Abt. Herzchirugie, Universitätsklinikum Heidelberg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Custodiol-N solution · Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride

Start the discussion